Senna

Corticosteroids promote urinary potassium wasting through mineralocorticoid receptor activation. Combined with senna gastrointestinal potassium losses via diarrhea, additive potassium depletion can cause severe hypokalemia with risk of muscle weakness, cardiac arrhythmias, and neuromuscular dysfunction. This interaction is documented in the German Commission E and EMA HMPC senna monographs.

Avoid prolonged concurrent use of senna with systemic corticosteroids. Monitor serum potassium (K+) and consider supplementation. Use senna only short-term if required. If hypokalemia develops (K+ <3.0 mEq/L), discontinue senna immediately.

Senna sennosides stimulate intestinal secretion causing potassium-rich diarrhea and hypokalemia. Low serum potassium sensitizes the myocardium to digoxin by reducing Na/K-ATPase affinity for potassium while maintaining digoxin binding, effectively increasing pharmacological digoxin effect at unchanged plasma concentrations. A population-based nested case-control study in heart failure patients confirmed a modest but significant increased risk of digoxin toxicity with sennoside co-exposure.

Monitor serum potassium and digoxin levels in patients using both senna and digoxin. Restrict senna use to short-term courses (≤1 week) in digoxin-treated patients. Signs of digoxin toxicity—anorexia, nausea, visual changes (yellow-green halos), arrhythmias—require urgent clinical assessment.

Both senna and potassium-depleting diuretics reduce body potassium through different mechanisms: senna via diarrhea-induced fecal potassium loss, and diuretics via renal potassium excretion. Combined use can precipitate severe hypokalemia (serum K+ <3 mEq/L), resulting in muscle weakness, paralysis, cardiac arrhythmias, and rhabdomyolysis. This interaction is explicitly recognized in the EMA/HMPC Community Herbal Monograph on Senna.

Avoid concurrent use of senna with potassium-depleting diuretics whenever possible. If both are necessary, closely monitor serum electrolytes (K+, Mg2+) and supplement potassium as needed. Senna should not be used for more than 1 week in diuretic-treated patients without clinical supervision.

Senna-induced diarrhea can alter warfarin absorption and enterohepatic cycling of vitamin K, reducing intestinal bacterial vitamin K production and total vitamin K availability. The net effect is typically an increase in warfarin anticoagulant activity and INR elevation. Dehydration from excessive diarrhea may also affect warfarin distribution.

Monitor INR if senna is used regularly in patients on warfarin. Instruct patients to use the minimum effective dose and shortest duration. Signs of over-anticoagulation (unusual bruising, blood in urine or stool) should prompt immediate INR testing and clinical assessment.

Senna reduces the GI absorption of estrone (conjugated equine estrogens) and ethinyl estradiol, likely by accelerating intestinal transit, reducing absorption time, and interrupting enterohepatic recirculation of estrogens. This can reduce plasma estrogen concentrations, reducing the efficacy of HRT for menopausal symptom management or reducing oral contraceptive efficacy.

Caution patients on HRT or oral contraceptives against frequent or excessive senna use. Oral contraceptive efficacy may be reduced during episodes of senna-induced diarrhea. Recommend barrier contraceptive methods during diarrhea episodes. Adjust HRT dose if symptoms of estrogen deficiency emerge.

Hypokalemia induced by chronic or excessive senna use can prolong the cardiac QT interval and potentiate proarrhythmic risk of antiarrhythmic drugs that cause QT prolongation (sotalol, amiodarone, quinidine). Electrolyte imbalance alters cardiac membrane potential, increasing susceptibility to ventricular tachycardia, including torsades de pointes.

Restrict senna use in patients on QT-prolonging antiarrhythmic agents to the minimum effective short-term dose. Monitor serum potassium and magnesium levels. Report cardiac symptoms (palpitations, syncope, chest pain) promptly. Avoid prolonged senna use in this population.